A CME/ANCC, ABIM MOC-eligible Activity
TO REGISTER
Click here to complete your registration.
If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.
DATES AND TIMES
AGENDA
Welcome and Introduction
Personalized Treatment for Progressive HER2-Positive Breast Cancer
New Horizons in HER2-Positive Breast Cancer Care
Q&A Session and Activity Roundup
PROGRAM DESCRIPTION
While In recent years, the treatment of HER2-positive metastatic breast cancer has improved significantly and become increasingly individualized. Several novel therapies have emerged that provide patients progressing on first-line therapy with improved treatment options that can be personalized to their individual treatment needs. Additionally, a novel subset of breast cancer comprising patients with low HER2 expression (IHC 1 or 2) has been identified that represents up to 40% of all metastatic breast cancer. Several novel agents are in development that specifically target this low HER2 expressing population
This activity, Personalized Approaches to HER2-Positive Breast Cancer Treatment, will provide oncology clinicians with information on the most recent treatments for HER2-positive breast cancer, expert recommendations for treatment selection and sequencing, and how to identify and treat HER2-positive patients with low HER2 expression.
STEERING COMMITTEE
Reshma L. Mahtani, DO
Chief of Breast Oncology
Miami Cancer Institute
Baptist Health South Florida
Plantation, FL
Marissa Marti-Smith, APRN, AGNP-C, AOCNP
Oncology Nurse Practitioner
Baylor Sammons Cancer Center
Dallas, TX
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Cambridge, MA
TARGET AUDIENCE
The intended audience for this educational initiative is oncologists, pathologists, nurses, and other clinicians involved in the treatment of patients with breast cancer.
EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to:
- Assess the safety and efficacy of currently approved treatments for HER2-positive MBC
- Develop patient-personalized treatment plans for patients with progressive HER2-positive MBC on the basis of patient and disease characteristics
- Evaluate patients with breast cancer for HER2 expression level
- Discuss emerging treatments in development for HER2 low expression MBC
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION STATEMENT
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email contact@potomacme.org.
NURSING ACCREDITATION STATEMENT
Nurses (ANCC)
Amedco LLC designates this activity for a maximum of 1 ANCC contact hour.
Click here to download the learner notification for the 2/1 program.
ABIM MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
ABMS MOC APPROVAL STATEMENT
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Personalized Approaches to HER2-Postive Breast Cancer has met the requirements as a Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:ABMS MOC Part II CME Activity
Family Medicine
DISCLOSURE INFORMATION
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of the activity is vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships will be mitigated by PCME.
Disclosure and mitigation information will be made known to the participants prior to the start of the activity.
FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
SYSTEM CHECK
To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.
HARDWARE REQUIREMENTS
WINDOWS
1.4 GHz Intel Pentium 4 or faster processor (or equivalent) Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit) 512 MB of RAM (1 GB recommended) Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
1.83 GHz Intel Core Duo or faster processor 512 MB RAM (1 GB recommended) Mac OS X 10.12, 10.13 and 10.14 Mozilla Firefox, Apple Safari, Google Chrome For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods) Google Android 4.4 or later Apple iOS: iOS 8.1.2 or later
SOFTWARE REQUIREMENTS
DSL/cable (wired connection recommended)
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT AND MOC POINTS
There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
This program is supported by educational grants from AstraZeneca, Daiichi Sankyo, And Seagen.
PCME Privacy Policy